The subgroup of high HRG expressing tumors showed increased PFS and has supported an ongoing phase III trial (NCT02134015).[106, 107] Phase I (NCT02350712) and phase II (NCT02633800) studies are currently testing the combination of patritumab with cetuximab and platinum-based therapy for HNSCC.[108] A phase Ib/II trial is also evaluating the combination of patritumab, trastuzumab and paclitaxel in first-line treatment of HER2-amplified breast cancers (NCT01512199). Here, ERBB2 is linked to head and neck squamous cell carcinoma.